RT Journal Article
SR Electronic
A1 Gordon, Debra
T1 Recent Data from LEAD
JF MD Conference Express
YR 2010
FD SAGE Publications
VO 10
IS 9
SP 18
OP 19
DO 10.1177/155989771009004
UL http://mdc.sagepub.com/content/10/9/18.abstract
AB In patients with diabetes, vascular conditions are responsible for the majority of morbidity, mortality, and cost that are attributed to the disease [Centers for Disease Control and Prevention. National Diabetes Fact Sheet. 2007]. The Liraglutide Effect and Action in Diabetes [LEAD; NCT00700817] trials are designed to evaluate the efficacy and safety of glucagon-like peptide-1 agonist compared with existing antidiabetic therapies.